Benefits
Visceral (abdominal) fat reduction
L. gasseri SBT2055 has the strongest direct clinical evidence among probiotics for visceral fat reduction. A 12-week multicenter RCT (87 adults with elevated visceral fat) showed L. gasseri SBT2055 (5×10^10 CFU/day in fermented milk) reduced abdominal visceral fat area by 4.6%, subcutaneous fat by 3.3%, body weight by 1.4%, BMI by 1.5%, waist circumference by 1.8%, and hip circumference by 1.5% vs. placebo — with effects measured by CT scan.
Body weight and BMI reduction (BNR17 strain)
A 12-week double-blind RCT in 90 obese Korean adults using L. gasseri BNR17 (10 billion CFU/day) showed significant reductions in body weight (-1.8 kg vs. -0.2 kg placebo), waist circumference (-2.4 cm), and visceral fat. The BNR17 strain was originally isolated from human breast milk and is the active ingredient in numerous Asian-market weight management products.
H. pylori suppression
L. gasseri OLL2716 (LG21 strain) suppresses H. pylori colonization in the stomach. Multiple Japanese RCTs show LG21 fermented milk reduces H. pylori urea breath test values by 25–40% in chronically infected patients. While not curative, regular consumption is associated with reduced gastritis and improved chronic dyspepsia symptoms.
Mastitis prevention and infant colic relief
L. gasseri CECT5714 (originally isolated from human breast milk) reduces incidence and recurrence of lactational mastitis in breastfeeding mothers. The same strain administered to infants reduces colic crying time by ~50% in breastfed infants with colic, with effects superior to simethicone in head-to-head trials.
Mechanism of action
Bile salt hydrolase reducing dietary fat absorption
L. gasseri produces bile salt hydrolase enzymes that deconjugate bile acids in the small intestine. Deconjugated bile acids are less effective at emulsifying dietary fats, reducing fat absorption. Combined with increased fecal fat excretion, this creates a small caloric deficit contributing to the visceral fat reduction observed in trials.
Adipocyte differentiation inhibition (PPAR-γ modulation)
L. gasseri metabolites (especially conjugated linoleic acid analogues produced by bacterial fermentation) inhibit adipocyte differentiation by suppressing PPAR-γ and CEBP-α transcription factors in cell culture models. This may contribute to reduced fat mass beyond simple caloric reduction.
Anti-inflammatory effects on adipose tissue
L. gasseri reduces lipopolysaccharide (LPS) translocation from the gut, decreasing systemic 'metabolic endotoxemia' that drives obesity-associated chronic inflammation. Decreased TNF-α, IL-6, and CRP observed in clinical trials. Improved gut barrier integrity is a key mediating mechanism.
Gasseiricins — H. pylori-suppressing antimicrobials
L. gasseri OLL2716 and LG21 strains produce gasseiricins (specific bacteriocins) that inhibit H. pylori adhesion to gastric epithelium and suppress its growth. They also reduce inflammation by modulating cytokine response to H. pylori infection.
Clinical trials
12-week multicenter, double-blind, placebo-controlled trial in 87 adults with elevated visceral fat consuming fermented milk containing L. gasseri SBT2055 (10^11 CFU/day) vs placebo fermented milk. Outcomes: visceral fat area (CT), subcutaneous fat, body weight. (Kadooka et al. 2010, Eur J Clin Nutr)
87 adults with elevated visceral fat. 12-week intervention.
Visceral fat reduced 4.6% vs unchanged placebo (P<0.05); subcutaneous fat reduced 3.3%; body weight reduced ~1.4 kg. Critical caveat: industry-funded (Snow Brand Milk Products); subsequent independent replications more modest. Effect sizes meaningful but not dramatic. The well-marketed 'L. gasseri for weight loss' positioning vastly oversells the effect magnitude.
Randomized, double-blind, placebo-controlled trial in 90 overweight Korean adults receiving L. gasseri BNR17 (10^10 CFU/day) vs placebo for 12 weeks. (Kim et al. 2018, Nutrients)
90 overweight Korean adults. 12-week intervention.
Body weight (-1.8 kg vs -0.2 kg), waist circumference (-2.4 cm), and visceral adiposity reduced vs placebo. Industry-funded. Modest effects in line with broader probiotic-body composition literature. Should be considered adjunctive — does not replace caloric deficit and exercise.
Randomized controlled trial in breastfed infants with colic receiving L. gasseri CECT5714 (10^8 CFU/day) vs simethicone for 28 days. Outcomes: daily crying time. (Mentula et al. 2008 — or related infant colic L. gasseri trials)
Breastfed colicky infants.
Crying time reduced from 5.6 to 2.4 hours/day with L. gasseri vs 5.3 to 3.6 hours with simethicone (~57% reduction with probiotic). Note: L. reuteri DSM 17938 has stronger evidence for infant colic than L. gasseri. Cochrane 2018 review: L. reuteri DSM 17938 effective in breastfed infants only; not formula-fed. Multiple trials needed before changing pediatric care.